Eric Angevin MD, PhD

Dr. Eric Angevin, MD-PhD, is since 2006 in charge of the development of industrial partnerships and collaborations as Alliance Manager at the institutional level of Gustave Roussy Cancer Center (Villejuif, France). He has an extended background in clinical and translational research with specific interests in the development of monoclonal antibodies/ADCs, immunotherapies, and precision medicine programs with an experience of more than 15 years as a senior investigator at the Drug Development Department (DITEP) of Gustave Roussy recognized as one of the largest early clinical trials facility in Europe. Dr Angevin has been involved in more than three hundred clinical trials including “first-in-human” studies and has been a contributor to more than 100 articles (h-index 39) in peer-reviewed international journals. He is an active member of the ASCO, AACR, ESMO, and TAT communities.